| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Bisphenol A bis(diphenyl phosphate) is an industrial flame retardant. It does not have a specific biological target for therapeutic purposes. Its mechanism of action is physical/chemical: it decomposes to release phosphoric acid, which promotes char formation (condensed phase action) and acts as a radical scavenger in the gas phase. Toxicologically, it is being studied as an environmental contaminant and potential endocrine disruptor (weak estrogenic activity due to bisphenol A backbone). It may bind weakly to the estrogen receptor (ER) at very high concentrations, but this is an off-target effect, not a therapeutic target.
|
|---|---|
| ln Vitro |
In vitro, BDP is not used for biological activity studies. It is an analytical standard. In an HPLC method, it is dissolved in acetonitrile (1 mg/mL). Calibration standards are prepared at 0.1-50 ug/mL. It is used to quantify BDP in polymer leachates or dust samples for environmental exposure assessment. It may show weak estrogenic activity in an MCF-7 cell proliferation assay (E-SCREEN) at high concentrations (>10 uM). It is also a plasticizer, used to melt-process polycarbonate/acrylonitrile-butadiene-styrene (PC/ABS) blends. It is not used for drug screening.
|
| ln Vivo |
In vivo, BDP is not administered for therapeutic purposes. It is used in animal studies to investigate the toxicokinetics and bioaccumulation of organophosphate flame retardants. In a 28-day oral feeding study in rats (e.g., 50-200 mg/kg/day), BDP may cause liver enlargement (hepatomegaly) and increased activity of liver enzymes (ALT, AST). It is not used in efficacy models. It is an industrial chemical used in plastics manufacturing.
|
| Enzyme Assay |
General protocol for in vitro analytical use: For HPLC analysis of flame retardants, prepare a 1 mg/mL stock solution in acetonitrile. Prepare calibration standards in acetonitrile at 0.1, 0.5, 1, 5, 10, 25, 50, 100 ug/mL. Use a C18 column (4.6 × 150 mm, 5 um) with mobile phase acetonitrile:water (70:30) at 1.0 mL/min. UV detection at 230 nm. For sample preparation, extract dust (100 mg) with 10 mL acetonitrile, sonicate, filter, and inject 20 uL. For LC-MS, use positive mode with m/z 693 [M+H]+. Store the compound at room temperature.
|
| Cell Assay |
General protocol for in vitro cell-based experiments: For an estrogenicity assay, culture MCF-7 cells in phenol red-free DMEM with 10% charcoal-stripped FBS. Seed in 96-well plates (1×10^4 cells/well). Treat with BDP (0.1-100 uM) for 48 h. Measure cell proliferation by MTT. Include 1 nM 17beta-estradiol as a positive control. BDP may show weak proliferative effects only at >10 uM. This is a toxicological assessment.
|
| Animal Protocol |
General protocol for in vivo animal experiments: For a toxicokinetic study, administer BDP (100 mg/kg, oral) in corn oil to male Sprague-Dawley rats (n=5). Collect blood at 0, 1, 2, 4, 8, 12, 24, 48 h. Extract plasma with ethyl acetate, evaporate, reconstitute, and analyze by HPLC-UV. The half-life is expected to be 6-12 hours. This study assesses systemic exposure, not therapeutic efficacy.
|
| ADME/Pharmacokinetics |
General pharmacokinetic properties: This compound (MW 692.63) is a high molecular weight, lipophilic solid or viscous liquid (LogP >5). It is insoluble in water but soluble in organic solvents. If absorbed, it would be metabolized by CYP450 enzymes (hydrolysis) to bisphenol A and diphenyl phosphate. Elimination half-life may be long (days) due to high lipophilicity. For storage, it is supplied as a solid or liquid, kept at room temperature in a sealed container. Stock solutions in acetonitrile are stable at -20degC for 6 months.
|
| Toxicity/Toxicokinetics |
General toxicity profile: BDP is a potential endocrine disruptor (weak estrogenicity) and may be toxic to aquatic life. It is an irritant. The oral LD50 in rats is >5000 mg/kg. Standard safety precautions (gloves, lab coat, fume hood) should be used. GHS hazard statements may include H411 (Toxic to aquatic life with long-lasting effects). For research use only.
|
| References | |
| Additional Infomation |
Bisphenol A bis(diphenyl phosphate) is also known as BDP, BPADP, or Aflammit PLF 100. It is a halogen-free flame retardant used as a replacement for brominated flame retardants. Its molecular formula is C39H34O8P2. The product is for research, analytical, and forensic use only, not for human consumption. Store in a cool, dry place.
|
| Molecular Formula |
C39H34O8P2
|
|---|---|
| Molecular Weight |
692.63
|
| Exact Mass |
692.173
|
| CAS # |
5945-33-5
|
| PubChem CID |
9874825
|
| Appearance |
Typically exists as solids at room temperature
|
| Hydrogen Bond Donor Count |
0
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
49
|
| Complexity |
931
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(C1=CC=C(C=C1)OP(=O)(OC2=CC=CC=C2)OC3=CC=CC=C3)C4=CC=C(C=C4)OP(=O)(OC5=CC=CC=C5)OC6=CC=CC=C6
|
| InChi Key |
BQPNUOYXSVUVMY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C39H34O8P2/c1-39(2,31-23-27-37(28-24-31)46-48(40,42-33-15-7-3-8-16-33)43-34-17-9-4-10-18-34)32-25-29-38(30-26-32)47-49(41,44-35-19-11-5-12-20-35)45-36-21-13-6-14-22-36/h3-30H,1-2H3
|
| Chemical Name |
[4-[2-(4-diphenoxyphosphoryloxyphenyl)propan-2-yl]phenyl] diphenyl phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4438 mL | 7.2189 mL | 14.4377 mL | |
| 5 mM | 0.2888 mL | 1.4438 mL | 2.8875 mL | |
| 10 mM | 0.1444 mL | 0.7219 mL | 1.4438 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
